Reirradiation for recurrent head and neck cancer

Expert Review of Anticancer Therapy

Volumn 12, Issue 9, 2012, Pages 1177-1189

  Patel, Pretesh R ^a   Salama, Joseph K ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

head and neck cancer; intensity modulated radiotherapy; reirradiation; stereotactic body radiotherapy

Indexed keywords

BEVACIZUMAB; BORTEZOMIB; CARBOPLATIN; CETUXIMAB; CISPLATIN; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; FLUOROURACIL; GEMCITABINE; GRANULOCYTE COLONY STIMULATING FACTOR; HYDROXYUREA; IRINOTECAN; MITOMYCIN; PACLITAXEL; TIRAPAZAMINE;

CANCER CONTROL; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER SURGERY; CONTINUOUS INFUSION; DISEASE FREE SURVIVAL; HEAD AND NECK CANCER; HUMAN; INOPERABLE CANCER; INTENSITY MODULATED RADIATION THERAPY; MULTIPLE CYCLE TREATMENT; PROGNOSIS; RECURRENT CANCER; REIRRADIATION; REVIEW; STEREOTACTIC BODY RADIATION THERAPY; SYSTEMIC THERAPY;

CRANIAL IRRADIATION; DOSE-RESPONSE RELATIONSHIP, RADIATION; EVIDENCE-BASED PRACTICE; HEAD AND NECK NEOPLASMS; HUMANS; NEOPLASM RECURRENCE, LOCAL; PATIENT CARE PLANNING; PATIENT SELECTION; RADIATION INJURIES; RADIOSURGERY; RADIOTHERAPY, INTENSITY-MODULATED; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RETREATMENT; RISK ASSESSMENT; SALVAGE THERAPY; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 84867950704     PISSN: 14737140     EISSN: 17448328     Source Type: Journal    
DOI: 10.1586/era.12.97     Document Type: Review

References (92)

1. Delaney G, Jacob S, Barton M. Estimation of an optimal external beam radiotherapy utilization rate for head and neck carcinoma. Cancer 103(11), 2216-2227 (2005). (Pubitemid 40686564)
2. Bernier J, Cooper JS, Pajak TF et al. Defining risk levels in locally advanced head and neck cancers: a comparative analysis of concurrent postoperative radiation plus chemotherapy trials of the EORTC (#22931) and RTOG (# 9501). Head Neck 27(10), 843-850 (2005). (Pubitemid 41395696)
3. Pignon JP, le Maître A, Maillard E, Bourhis J; MACH-NC Collaborative Group. Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): an update on 93 randomised trials and 17,346 patients. Radiother. Oncol. 92(1), 4-14 (2009).
4. Ang KK, Harris J, Wheeler R et al. Human papillomavirus and survival of patients with oropharyngeal cancer. N. Engl. J. Med. 363(1), 24-35 (2010).
5. Bernier J, Domenge C, Ozsahin M et al. European Organization for Research and Treatment of Cancer Trial 22931. Postoperative irradiation with or without concomitant chemotherapy for locally advanced head and neck cancer. N. Engl. J. Med. 350(19), 1945-1952 (2004). (Pubitemid 38580197)
6. Cooper JS, Pajak TF, Forastiere AA et al.; Radiation Therapy Oncology Group 9501/ Intergroup. Postoperative concurrent radiotherapy and chemotherapy for high-risk squamous-cell carcinoma of the head and neck. N. Engl. J. Med. 350(19), 1937-1944 (2004).
7. Forastiere AA, Goepfert H, Maor M et al.; Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancer. N. Engl. J. Med. 349(22), 2091-2098 (2003). (Pubitemid 37464533)
8. Posner MR, Hershock DM, Blajman CR et al.; TAX 324 Study Group. Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer. N. Engl. J. Med. 357(17), 1705-1715 (2007). (Pubitemid 350005152)
9. Dayyani F, Etzel CJ, Liu M, Ho CH, Lippman SM, Tsao AS. Meta-analysis of the impact of human papillomavirus (HPV) on cancer risk and overall survival in head and neck squamous cell carcinomas (HNSCC). Head Neck Oncol. 2, 15 (2010).
10. Cooper JS, Pajak TF, Rubin P et al. Second malignancies in patients who have head and neck cancer: incidence, effect on survival and implications based on the RTOG experience. Int. J. Radiat. Oncol. Biol. Phys. 17(3), 449-456 (1989). (Pubitemid 19227546)
11. Zafereo ME, Hanasono MM, Rosenthal DI et al. The role of salvage surgery in patients with recurrent squamous cell carcinoma of the oropharynx. Cancer 115(24), 5723-5733 (2009).
12. Nishijima W, Takooda S, Tokita N, Takayama S, Sakura M. Analyses of distant metastases in squamous cell carcinoma of the head and neck and lesions above the clavicle at autopsy. Arch. Otolaryngol. Head Neck Surg. 119(1), 65-68 (1993). (Pubitemid 23033254)
13. Vermorken JB, Mesia R, Rivera F et al. Platinum-based chemotherapy plus cetuximab in head and neck cancer. N. Engl. J. Med. 359(11), 1116-1127 (2008).
14. Argiris A, Li Y, Forastiere A. Prognostic factors and long-term survivorship in patients with recurrent or metastatic carcinoma of the head and neck. Cancer 101(10), 2222-2229 (2004).
15. Peiffert D, Pernot M, Malissard L et al. Salvage irradiation by brachytherapy of velotonsillar squamous cell carcinoma in a previously irradiated field: results in 73 cases. Int. J. Radiat. Oncol. Biol. Phys. 29(4), 681-686 (1994). (Pubitemid 24241306)
16. Kwong DL, Nicholls J, Wei WI et al. The time course of histologic remission after treatment of patients with nasopharyngeal carcinoma. Cancer 85(7), 1446-1453 (1999). (Pubitemid 29152815)
17. Brouwer J, Bodar EJ, De Bree R et al. Detecting recurrent laryngeal carcinoma after radiotherapy: room for improvement. Eur. Arch. Otorhinolaryngol. 261(8), 417-422 (2004). (Pubitemid 39304396)
18. Rosenthal DI, Asper JA, Barker JL Jr et al. Importance of patient examination to clinical quality assurance in head and neck radiation oncology. Head Neck 28(11), 967-973 (2006). (Pubitemid 44630935)
19. Gourin CG, Watts T, Williams HT, Patel VS, Bilodeau PA, Coleman TA. Identification of distant metastases with PET-CT in patients with suspected recurrent head and neck cancer. Laryngoscope 119(4), 703-706 (2009).
20. Perlow A, Bui C, Shreve P, Sundgren PC, Teknos TN, Mukherji SK. High incidence of chest malignancy detected by FDG PET in patients suspected of recurrent squamous cell carcinoma of the upper aerodigestive tract. J. Comput. Assist. Tomogr. 28(5), 704-709 (2004). (Pubitemid 39195549)
21. Ng SH, Chan SC, Yen TC et al. Comprehensive imaging of residual/ recurrent nasopharyngeal carcinoma using whole-body MRI at 3 T compared with FDG-PET-CT. Eur. Radiol. 20(9), 2229-2240 (2010).
22. Comoretto M, Balestreri L, Borsatti E, Cimitan M, Franchin G, Lise M. Detection and restaging of residual and/or recurrent nasopharyngeal carcinoma after chemotherapy and radiation therapy: comparison of MR imaging and FDG PET/CT. Radiology 249(1), 203-211 (2008).
23. Bachar GY, Goh C, Goldstein DP, O'Sullivan B, Irish JC. Long-term outcome analysis after surgical salvage for recurrent tonsil carcinoma following radical radiotherapy. Eur. Arch. Otorhinolaryngol. 267(2), 295-301 (2010).
24. Nichols AC, Kneuertz PJ, Deschler DG et al. Surgical salvage of the oropharynx after failure of organ-sparing therapy. Head Neck 33(4), 516-524 (2011).
25. Parsons JT, Mendenhall WM, Stringer SP, Cassisi NJ, Million RR. Salvage surgery following radiation failure in squamous cell carcinoma of the supraglottic larynx. Int. J. Radiat. Oncol. Biol. Phys. 32(3), 605-609 (1995).
26. Taussky D, Dulguerov P, Allal AS. Salvage surgery after radical accelerated radiotherapy with concomitant boost technique for head and neck carcinomas. Head Neck 27(3), 182-186 (2005). (Pubitemid 40315766)
27. Goodwin WJ Jr. Salvage surgery for patients with recurrent squamous cell carcinoma of the upper aerodigestive tract: when do the ends justify the means? Laryngoscope 110(3 Pt 2 Suppl. 93), 1-18 (2000). (Pubitemid 30141742)
28. Temam S, Koka V, Mamelle G et al. Treatment of the N0 neck during salvage surgery after radiotherapy of head and neck squamous cell carcinoma. Head Neck 27(8), 653-658 (2005). (Pubitemid 41113765)
29. De Crevoisier R, Domenge C, Wibault P et al. Full dose reirradiation combined with chemotherapy after salvage surgery in head and neck carcinoma. Cancer 91(11), 2071-2076 (2001). (Pubitemid 32476371)
30. Kasperts N, Slotman BJ, Leemans CR, de Bree R, Doornaert P, Langendijk JA. Results of postoperative reirradiation for recurrent or second primary head and neck carcinoma. Cancer 106(7), 1536-1547 (2006).
31. Machtay M, Rosenthal DI, Chalian AA et al. Pilot study of postoperative reirradiation, chemotherapy, and amifostine after surgical salvage for recurrent head-and-neck cancer. Int. J. Radiat. Oncol. Biol. Phys. 59(1), 72-77 (2004). (Pubitemid 38501509)
32. Salama JK, Vokes EE, Chmura SJ et al. Long-term outcome of concurrent chemotherapy and reirradiation for recurrent and second primary head-andneck squamous cell carcinoma. Int. J. Radiat. Oncol. Biol. Phys. 64(2), 382-391 (2006). (Pubitemid 43083422)
33. De Crevoisier R, Bourhis J, Domenge C et al. Full-dose reirradiation for unresectable head and neck carcinoma: experience at the Gustave-Roussy Institute in a series of 169 patients. J. Clin. Oncol. 16(11), 3556-3562 (1998). (Pubitemid 28506768)
34. Haraf DJ, Weichselbaum RR, Vokes EE. Re-irradiation with concomitant chemotherapy of unresectable recurrent head and neck cancer: a potentially curable disease. Ann. Oncol. 7(9), 913-918 (1996). (Pubitemid 26426265)
35. Janot F, de Raucourt D, Benhamou E et al. Randomized trial of postoperative reirradiation combined with chemotherapy after salvage surgery compared with salvage surgery alone in head and neck carcinoma. J. Clin. Oncol. 26(34), 5518-5523 (2008).
36. McDonald MW, Lawson J, Garg MK et al.; Expert Panel on Radiation Oncology-Head and Neck Cancer. ACR appropriateness criteria retreatment of recurrent head and neck cancer after prior definitive radiation expert panel on radiation oncology-head and neck cancer. Int. J. Radiat. Oncol. Biol. Phys. 80(5), 1292-1298 (2011).
37. Choe KS, Haraf DJ, Solanki A et al. Prior chemoradiotherapy adversely impacts outcomes of recurrent and second primary head and neck cancer treated with concurrent chemotherapy and reirradiation. Cancer 117(20), 4671-4678 (2011).
38. Kramer NM, Horwitz EM, Cheng J et al. Toxicity and outcome analysis of patients with recurrent head and neck cancer treated with hyperfractionated split-course reirradiation and concurrent cisplatin and paclitaxel chemotherapy from two prospective Phase I and II studies. Head Neck 27(5), 406-414 (2005). (Pubitemid 40593895)
39. Langendijk JA, Kasperts N, Leemans CR, Doornaert P, Slotman BJ. A Phase II study of primary reirradiation in squamous cell carcinoma of head and neck. Radiother. Oncol. 78(3), 306-312 (2006).
40. Langer CJ, Harris J, Horwitz EM et al. Phase II study of low-dose paclitaxel and cisplatin in combination with split-course concomitant twice-daily reirradiation in recurrent squamous cell carcinoma of the head and neck: results of Radiation Therapy Oncology Group Protocol 9911. J. Clin. Oncol. 25(30), 4800-4805 (2007). (Pubitemid 350086484)
41. Lee N, Chan K, Bekelman JE et al. Salvage re-irradiation for recurrent head and neck cancer. Int. J. Radiat. Oncol. Biol. Phys. 68(3), 731-740 (2007). (Pubitemid 46818729)
42. Spencer SA, Harris J, Wheeler RH et al. RTOG 96-10: reirradiation with concurrent hydroxyurea and 5-fluorouracil in patients with squamous cell cancer of the head and neck. Int. J. Radiat. Oncol. Biol. Phys. 51(5), 1299-1304 (2001). (Pubitemid 33116324)
43. Spencer SA, Harris J, Wheeler RH et al. Final report of RTOG 9610, a multiinstitutional trial of reirradiation and chemotherapy for unresectable recurrent squamous cell carcinoma of the head and neck. Head Neck 30(3), 281-288 (2008). (Pubitemid 351480742)
44. Tortochaux J, Tao Y, Tournay E et al. Randomized Phase III trial (GORTEC 98-03) comparing re-irradiation plus chemotherapy versus methotrexate in patients with recurrent or a second primary head and neck squamous cell carcinoma, treated with a palliative intent. Radiother. Oncol. 100(1), 70-75 (2011).
45. Bentzen SM, Trotti A. Evaluation of early and late toxicities in chemoradiation trials. J. Clin. Oncol. 25(26), 4096-4103 (2007). (Pubitemid 47492954)
46. Vokes EE, Panje WR, Schilsky RL et al. Hydroxyurea, fluorouracil, and concomitant radiotherapy in poorprognosis head and neck cancer: a Phase I-II study. J. Clin. Oncol. 7(6), 761-768 (1989). (Pubitemid 19145598)
47. Brockstein B, Haraf DJ, Stenson K et al. Phase I study of concomitant chemoradiotherapy with paclitaxel, fluorouracil, and hydroxyurea with granulocyte colony-stimulating factor support for patients with poor-prognosis cancer of the head and neck. J. Clin. Oncol. 16(2), 735-744 (1998). (Pubitemid 28135623)
48. Brizel DM, Albers ME, Fisher SR et al. Hyperfractionated irradiation with or without concurrent chemotherapy for locally advanced head and neck cancer. N. Engl. J. Med. 338(25), 1798-1804 (1998). (Pubitemid 28277960)
49. Calais G, Alfonsi M, Bardet E et al. Randomized trial of radiation therapy versus concomitant chemotherapy and radiation therapy for advanced-stage oropharynx carcinoma. J. Natl Cancer Inst. 91(24), 2081-2086 (1999). (Pubitemid 30019568)
50. Glisson BS, Murphy BA, Frenette G, Khuri FR, Forastiere AA. Phase II Trial of docetaxel and cisplatin combination chemotherapy in patients with squamous cell carcinoma of the head and neck. J. Clin. Oncol. 20(6), 1593-1599 (2002). (Pubitemid 34260540)
51. Upile T, Triaridis S, Kirkland P et al. The management of carotid artery rupture. Eur. Arch. Otorhinolaryngol. 262(7), 555-560 (2005). (Pubitemid 41159117)
52. McDonald MW, Moore MG, Johnstone PA. Risk of carotid blowout after reirradiation of the head and neck: a systematic review. Int. J. Radiat. Oncol. Biol. Phys. 82(3), 1083-1089 (2012).
53. Chang FC, Lirng JF, Luo CB et al. Patients with head and neck cancers and associated postirradiated carotid blowout syndrome: endovascular therapeutic methods and outcomes. J. Vasc. Surg. 47(5), 936-945 (2008).
54. Warren FM, Cohen JI, Nesbit GM, Barnwell SL, Wax MK, Andersen PE. Management of carotid 'blowout' with endovascular stent grafts. Laryngoscope 112(3), 428-433 (2002). (Pubitemid 34225855)
55. Zussman B, Gonzalez LF, Dumont A et al. Endovascular management of carotid blowout. World Neurosurg. 78(1-2), 109-114 (2011).
56. Sulman EP, Schwartz DL, Le TT et al. IMRT reirradiation of head and neck cancer-disease control and morbidity outcomes. Int. J. Radiat. Oncol. Biol. Phys. 73(2), 399-409 (2009).
57. Nutting CM, Morden JP, Harrington KJ et al.; PARSPORT trial management group. Parotid-sparing intensity modulated versus conventional radiotherapy in head and neck cancer (PARSPORT): a Phase 3 multicentre randomised controlled trial. Lancet Oncol. 12(2), 127-136 (2011).
58. Biagioli MC, Harvey M, Roman E et al. Intensity-modulated radiotherapy with concurrent chemotherapy for previously irradiated, recurrent head and neck cancer. Int. J. Radiat. Oncol. Biol. Phys. 69(4), 1067-1073 (2007). (Pubitemid 47625850)
59. Duprez F, Madani I, Bonte K et al. Intensity-modulated radiotherapy for recurrent and second primary head and neck cancer in previously irradiated territory. Radiother. Oncol. 93(3), 563-569 (2009).
60. Sher DJ, Haddad RI, Norris CM Jr et al. Efficacy and toxicity of reirradiation using intensity-modulated radiotherapy for recurrent or second primary head and neck cancer. Cancer 116(20), 4761-4768 (2010).
61. Kharofa J, Choong N, Wang D et al. Continuous-course reirradiation with concurrent carboplatin and paclitaxel for locally recurrent, nonmetastatic squamous cell carcinoma of the head-and-neck. Int. J. Radiat. Oncol. Biol. Phys. 83(2), 690-695 (2012).
62. Chen AM, Farwell DG, Luu Q, Cheng S, Donald PJ, Purdy JA. Prospective trial of high-dose reirradiation using daily image guidance with intensity-modulated radiotherapy for recurrent and second primary head-and-neck cancer. Int. J. Radiat. Oncol. Biol. Phys. 80(3), 669-676 (2011).
63. Popovtzer A, Gluck I, Chepeha DB et al. The pattern of failure after reirradiation of recurrent squamous cell head and neck cancer: implications for defining the targets. Int. J. Radiat. Oncol. Biol. Phys. 74(5), 1342-1347 (2009).
64. Watkins JM, Shirai KS, Wahlquist AE et al. Toxicity and survival outcomes of hyperfractionated split-course reirradiation and daily concurrent chemotherapy in locoregionally recurrent, previously irradiated head and neck cancers. Head Neck 31(4), 493-502 (2009).
65. Bertelsen A, Hansen CR, Johansen J, Brink C. Single arc volumetric modulated arc therapy of head and neck cancer. Radiother. Oncol. 95(2), 142-148 (2010).
66. Garcia-Barros M, Paris F, Cordon-Cardo C et al. Tumor response to radiotherapy regulated by endothelial cell apoptosis. Science 300(5622), 1155-1159 (2003). (Pubitemid 36583102)
67. Lo SS, Fakiris AJ, Chang EL et al. Stereotactic body radiation therapy: a novel treatment modality. Nat. Rev. Clin. Oncol. 7(1), 44-54 (2010).
68. Timmerman R, Paulus R, Galvin J et al. Stereotactic body radiation therapy for inoperable early stage lung cancer. JAMA 303(11), 1070-1076 (2010).
69. Salama JK, Hasselle MD, Chmura SJ et al. Stereotactic body radiotherapy for multisite extracranial oligometastases: final report of a dose escalation trial in patients with 1 to 5 sites of metastatic disease. Cancer 118(11), 2962-2970 (2012).
70. Cengiz M, Özyigit G, Yazici G et al. Salvage reirradiaton with stereotactic body radiotherapy for locally recurrent head-andneck tumors. Int. J. Radiat. Oncol. Biol. Phys. 81(1), 104-109 (2011).
71. Heron DE, Ferris RL, Karamouzis M et al. Stereotactic body radiotherapy for recurrent squamous cell carcinoma of the head and neck: results of a Phase I dose-escalation trial. Int. J. Radiat. Oncol. Biol. Phys. 75(5), 1493-1500 (2009).
72. Heron DE, Rwigema JC, Gibson MK, Burton SA, Quinn AE, Ferris RL. Concurrent cetuximab with stereotactic body radiotherapy for recurrent squamous cell carcinoma of the head and neck: a single institution matched case-control study. Am. J. Clin. Oncol. 34(2), 165-172 (2011).
73. Kawaguchi K, Sato K, Horie A et al. Stereotactic radiosurgery may contribute to overall survival for patients with recurrent head and neck carcinoma. Radiat. Oncol. 5, 51 (2010).
74. Roh KW, Jang JS, Kim MS et al. Fractionated stereotactic radiotherapy as reirradiation for locally recurrent head and neck cancer. Int. J. Radiat. Oncol. Biol. Phys. 74(5), 1348-1355 (2009).
75. Rwigema JC, Heron DE, Ferris RL et al. The impact of tumor volume and radiotherapy dose on outcome in previously irradiated recurrent squamous cell carcinoma of the head and neck treated with stereotactic body radiation therapy. Am. J. Clin. Oncol. 34(4), 372-379 (2011).
76. Siddiqui F, Patel M, Khan M et al. Stereotactic body radiation therapy for primary, recurrent, and metastatic tumors in the head-and-neck region. Int. J. Radiat. Oncol. Biol. Phys. 74(4), 1047-1053 (2009).
77. Unger KR, Lominska CE, Deeken JF et al. Fractionated stereotactic radiosurgery for reirradiation of head-and-neck cancer. Int. J. Radiat. Oncol. Biol. Phys. 77(5), 1411-1419 (2010).
78. Vargo JA, Wegner RE, Heron DE et al. Stereotactic body radiation therapy for locally recurrent, previously irradiated nonsquamous cell cancers of the head and neck. Head Neck 34(8), 1153-1161 (2011).
79. Rwigema JC, Heron DE, Ferris RL et al. Fractionated stereotactic body radiation therapy in the treatment of previouslyirradiated recurrent head and neck carcinoma: updated report of the University of Pittsburgh experience. Am. J. Clin. Oncol. 33(3), 286-293 (2010).
80. Lin JC, Jan JS. Locally advanced nasopharyngeal cancer: long-term outcomes of radiation therapy. Radiology 211(2), 513-518 (1999).
81. Feehan PE, Castro JR, Phillips TL et al. Recurrent locally advanced nasopharyngeal carcinoma treated with heavy charged particle irradiation. Int. J. Radiat. Oncol. Biol. Phys. 23(4), 881-884 (1992).
82. Jensen AD, Nikoghosyan A, Ellerbrock M, Ecker S, Debus J, Münter MW. Re-irradiation with scanned charged particle beams in recurrent tumours of the head and neck: acute toxicity and feasibility. Radiother. Oncol. 101(3), 383-387 (2011).
83. Villaflor VM, Haraf D, Salama JK et al. Phase II trial of pemetrexed-based induction chemotherapy followed by concomitant chemoradiotherapy in previously irradiated patients with squamous cell carcinoma of the head and neck. Ann. Oncol. 22(11), 2501-2507 (2011).
84. Dische S. Chemical sensitizers for hypoxic cells: a decade of experience in clinical radiotherapy. Radiother. Oncol. 3(2), 97-115 (1985). (Pubitemid 15170205)
85. Seiwert TY, Haraf DJ, Cohen EE et al. Phase I study of bevacizumab added to fluorouracil- and hydroxyurea-based concomitant chemoradiotherapy for poor-prognosis head and neck cancer. J. Clin. Oncol. 26(10), 1732-1741 (2008).
86. Bonner JA, Harari PM, Giralt J et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N. Engl. J. Med. 354(6), 567-578 (2006). (Pubitemid 43209104)
87. Balermpas P, Hambek M, Seitz O, Rödel C, Weiss C. Combined cetuximab and reirradiation for locoregional recurrent and inoperable squamous cell carcinoma of the head and neck. Strahlenther. Onkol. 185(12), 775-781 (2009).
88. Zwicker F, Roeder F, Thieke C et al. IMRT reirradiation with concurrent cetuximab immunotherapy in recurrent head and neck cancer. Strahlenther. Onkol. 187(1), 32-38 (2011).
89. Kao J, Genden EM, Chen CT et al. Phase I trial of concurrent erlotinib, celecoxib, and reirradiation for recurrent head and neck cancer. Cancer 117(14), 3173-3181 (2011).
90. Rusthoven KE, Feigenberg SJ, Raben D et al. Initial results of a Phase I doseescalation trial of concurrent and maintenance erlotinib and reirradiation for recurrent and new primary head-and-neck cancer. Int. J. Radiat. Oncol. Biol. Phys. 78(4), 1020-1025 (2010).
91. Van Waes C, Chang AA, Lebowitz PF et al. Inhibition of nuclear factor-kappaB and target genes during combined therapy with proteasome inhibitor bortezomib and reirradiation in patients with recurrent head-and-neck squamous cell carcinoma. Int. J. Radiat. Oncol. Biol. Phys. 63(5), 1400-1412 (2005). (Pubitemid 41628035)
92. Dean NR, Rosenthal EL, Carroll WR et al. Robotic-assisted surgery for primary or recurrent oropharyngeal carcinoma. Arch. Otolaryngol. Head Neck Surg. 136(4), 380-384 (2010).